The Role of Induction (Neoadjuvant) Chemotherapy in Stage IIIA NSCLC

Rosell, Rafael; Font, Albert; Pifarré, Alex; Canela, Mercedes; Maurel, Joan; Arellano, Antonio; Izquierdo, José Luis

doi:10.1378/chest.109.5_supplement.102s

Cited by 42 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Several prior studies have explored the use of induction therapy followed by surgical resection. 3,[17][18][19][20][21][22][23] Two studies of neoadjuvant chemotherapy alone showed significant improvements in survival, 17,18 whereas others have shown only marginal effects.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers

Shaikh¹,

Haraf²,

Salama³

et al. 2007

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers

Shaikh¹,

Haraf²,

Salama³

et al. 2007

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…There are several reasons for using systemic therapy prior to resection [4]. Firstly, preoperative chemotherapy has the potential to control systemic disease, the major cause of death.…”

Section: Initial Trials Of Neoadjuvant Chemo-therapymentioning

confidence: 99%

Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

Felip¹,

Rosell

2002

CMC

Self Cite

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a systemic illness. More than half of those patients who present with stage I-IIIA disease and are resected will experience distant relapse. Postoperative adjuvant chemotherapy has been evaluated in several randomized trials but the results of these trials have been inconclusive with increased survival reported in few trials. In resectable stage IIIA NSCLC the findings of three randomized trials have indicated that the survival of these patients is better with neoadjuvant chemotherapy plus surgical resection than with resection alone. Phase II trials using preoperative concurrent chemoradiotherapy have been carried out with encouraging results. The majority of patients with stage IIIA NSCLC require multimodality therapy if they are to achieve a 5-year survival. Combined modality treatment in locally advanced NSCLC continues to evolve and is a subject of ongoing research. One focus for present research is to integrate new active agents into the neoadjuvant setting. Another challenge is to find better treatment approaches in earlier stages of disease. Some data suggest that induction chemotherapy in stage I-II is feasible, does not appear to compromise surgery and yields high response rates. A further aim is to use molecular biological markers of malignancy to identify patients at highest risk of metastatic relapse.

show abstract

“…By itself, thoracic radiotherapy provides local control and effective palliation of tumor-related symptoms but has minimal impact on the survival of these patients [4]. The majority of patients with Stage IIIA NSCLC require multimodality therapy if they are to achieve a 5-year survival [5]. There are several reasons for using systemic therapy prior to resection.…”

Section: Induction Chemotherapy With or Without Radiotherapy Followedmentioning

confidence: 99%